Although it is well recognized that KRAS, CDKN2A, SMAD4 and TP53 are major driver genes in pancreatic cancer, thus far these genetic alterations have not been exploited effectively for therapeutic benefits. This evidence concerns the gene CDKN2A and familial pancreatic carcinoma.